Tetraxetan

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu) . Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) [1][2][3].

60239-18-1

DOTA

12352200

H302, H315, H319, H335

Biochemical Assay Reagents; Radionuclide-Drug Conjugates (RDCs)

Antibody-drug Conjugate/ADC Related; Others

Cancer

99.95

H2O : 100 mg/mL (ultrasonic)

O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1

C16H28N4O8

404.42

H302, H315, H319, H335

[1]Orcutt KD, et al. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011 Apr;13 (2) :215-21. |[2]Decristoforo C, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008 Aug;35 (8) :1507-15. |[3]Müller C, et al. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013 Jan;54 (1) :124-31.

Room Temperature

4°C (Powder, protect from light)

http://file.medchemexpress.com/batch_PDF/HY-W053583/Tetraxetan-SDS-MedChemExpress.pdf

Biochemical Assay Reagents

Phase 2